Physician

Allen L Cohn, MD

According to 2025 Medicare claims, Allen Cohn, MD (NPI: 1316921976) practices hematology/oncology in the Denver-Aurora-Centennial, CO market, with the plurality of this provider's patient population coming from Denver, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 80218-1237. Cohn is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Cohn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 536 traditional Medicare patients, billed 63,458 HCPCS/CPT codes, and received $1,611,293 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 758 prescription claims across 132 beneficiaries totaling $1,140,557 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 134 claims. Open Payments data shows 221 records totaling $4,107,512. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,280,995 and ending at $1,611,293. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,194,210 and ending at $1,140,557. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $23,095 to $6,027.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	517	66,480	$1,280,995
2016	592	76,656	$1,483,569
2017	604	103,402	$2,024,206
2018	562	100,803	$2,599,498
2019	550	93,506	$1,997,876
2020	597	119,787	$2,467,207
2021	534	81,428	$1,874,031
2022	544	64,793	$1,965,924
2023	590	62,126	$2,213,578
2024	536	63,458	$1,611,293

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	165	1,336	$1,194,210
2016	155	1,177	$926,320
2017	183	1,385	$1,105,574
2018	187	1,507	$2,022,906
2019	177	1,013	$861,539
2020	161	996	$826,620
2021	154	841	$844,935
2022	154	796	$802,730
2023	133	738	$1,151,580
2024	132	758	$1,140,557

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	36	406	$80,369
2016	38	266	$73,645
2017	36	233	$37,772
2018	25	244	$49,754
2019	31	223	$57,200
2020	N/R	125	$9,981
2021	22	135	$9,035
2022	29	234	$45,599
2023	N/R	51	$9,793
2024	12	134	$3,535

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	103	111	$1,243
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	282	1,323	$97
80053	Blood test, comprehensive group of blood chemicals	177	1,121	$10
36415	Insertion of needle into vein for collection of blood sample	248	750	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	182	1,108	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	11	330	$193,062
Xtandi	Enzalutamide	12	360	$171,332
Creon	Lipase/Protease/Amylase	27	732	$54,807
Zenpep	Lipase/Protease/Amylase	23	639	$36,365
Eliquis	Apixaban	22	1,120	$23,225

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	38	$1,270
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	12	46	$866
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	21	$617
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	11	$556
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	18	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$264	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	216	$4,107,248	Aveo Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Allen L. Cohn, MD?

Tedicare shows public-source Medicare data for Allen L. Cohn, MD (NPI 1316921976), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Allen L. Cohn, MD have ACO affiliation data?

Allen L. Cohn, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Allen L. Cohn, MD?

Allen L. Cohn, MD is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Allen L. Cohn, MD have Open Payments data?

Allen L. Cohn, MD has 221 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.